John Valliere-Douglass is the Associate Director and Mass Spectrometry Core Group Leader at Seagen (formerly, Seattle Genetics). John works in the Analytical Sciences division within Seagen’s development arm, using proteomics techniques to scale and manufacture therapeutic modalities in significant quantities to support clinical trials. Seagen is most well-known for developing antibody-drug conjugates, a therapeutic modality gaining prominence especially for their use as targeted cancer therapies. In this episode, we discuss his biotechnology career trajectory from previous roles at Corixa and Amgen, highlighting the various new skills and differences between small biotech to large pharma along the way. John also shares his expertise on utilizing mass spectrometry in drug development, preparing products for regulatory submissions as well as the necessary considerations for running these assays. In addition to his work at Seagen, John has an extensive publishing and presentation record, recently serving as co-chair of the CASSS Mass Spectrometry Conference organizing committee, and he generously shares his advice for being an effective communicator and group leader with us. 

Hosted by Roshan Chikarmane  and Jenna Glatzer.